CNIPA.AI

Company patentsCompare

HEAD TO HEAD

AmazonAstraZeneca

Technology portfolios compared in the same window and counting units. Scale is compared only within the same field or subclass.

Same window · published 2025-01-01 — 2025-12-31Some name or date coverage is incomplete; affected counts are lower bounds

This is a structural comparison of collected portfolios. The same requested window does not establish equal entity scope, covered months or industry; no competitive ranking is inferred.

Applicant-name coverage differs. The counts below cover only the listed names and do not represent complete company portfolios.

Amazon: Applicant names included in these statistics — AMAZON TECH INCReviewed names not covered — AMAZON TECHNOLOGIES INC · AMAZON TECHNOLOGIES INC. · AMAZON TECHNOLOGIES, INC · AMAZON TECHNOLOGIES, INC.

AstraZeneca: Applicant names included in these statistics — ASTRAZENECA AB · ASTRAZENECA UK LTDReviewed names not covered — ASTRAZENECA UK LIMITED

Publications
2,095
Invention share
93%
Concentration
0.54
Green technology
—
Publications
957
Invention share
42%
Concentration
1.00
Green technology
—
0.01Field similarity
Cosine similarity of application counts across 35 fields. 1 is identical, 0 is no overlap.

01Technology field mirror

The 12 fields with the largest combined share. Share shows structure; count shows scale.

Technology field mirror
AmazonTechnology fieldAstraZeneca
0.2%
Pharmaceuticals
89.6%
65.9%
Computer technology
0.3%
0%
Organic fine chemistry
34.3%
29.5%
Digital communication
0%
0.6%
Biotechnology
26.7%
7.9%
IT methods for management
0.1%
7%
Audio-visual technology
0%
0.7%
Medical technology
5.7%
4.9%
Handling
1.2%
5.2%
Control
0.2%
3.8%
Measurement
0.7%
4%
Telecommunications
0%

Inspect one technology field

Inspect collected applications, portfolio share and supporting publications within one field. A technology overlap does not establish that companies in different industries are direct competitors.

One application may belong to multiple fields, so shares can sum to more than 100%. Drill-down lists publications; an application publication and its grant may appear separately.

02Same problem: shared IPC subclasses

The 10 subclasses in every company's top 60 with the most combined applications. Scale is compared within a subclass, never across different business scopes.

G06FData processing
Amazon912
AstraZeneca1
A61K
Amazon4
AstraZeneca770
G06NComputing models, AI
Amazon257
AstraZeneca1
G06QBusiness data processing
Amazon154
AstraZeneca1
G06VImage and video recognition
Amazon138
AstraZeneca1
G06TImage processing
Amazon101
AstraZeneca1
G01NAnalysing materials
Amazon11
AstraZeneca28
B65DContainers, packaging
Amazon8
AstraZeneca11
C12QBiochemical testing
Amazon11
AstraZeneca5
G16H
Amazon6
AstraZeneca7

03Where each one leans

Observed emphasis within each company’s collected top-60 IPC subclasses. A dash for another company means outside its top-60 list, not zero applications or a market gap. Incomplete coverage can also change the ordering.

Amazon

  • G06FData processing
    Amazon
    912
    AstraZeneca
    1
  • H04LDigital transmission
    Amazon
    442
    AstraZeneca
    —
  • G10LSpeech processing
    Amazon
    275
    AstraZeneca
    —
  • G06NComputing models, AI
    Amazon
    257
    AstraZeneca
    1
  • G06QBusiness data processing
    Amazon
    154
    AstraZeneca
    1
  • G06VImage and video recognition
    Amazon
    138
    AstraZeneca
    1

AstraZeneca

  • A61K
    Amazon
    4
    AstraZeneca
    770
  • A61P
    Amazon
    —
    AstraZeneca
    716
  • C07DHeterocyclic compounds
    Amazon
    —
    AstraZeneca
    288
  • C07K
    Amazon
    —
    AstraZeneca
    197
  • C12NMicroorganisms, enzymes
    Amazon
    —
    AstraZeneca
    70
  • G01NAnalysing materials
    Amazon
    11
    AstraZeneca
    28

04Publication rhythm

AmazonAstraZenecaPublications per period
Publications per period
PeriodAmazonAstraZeneca
2025-01≥242 (partial coverage)≥79 (partial coverage)
2025-02≥149 (partial coverage)≥83 (partial coverage)
2025-03≥130 (partial coverage)≥111 (partial coverage)
2025-04≥168 (partial coverage)≥93 (partial coverage)
2025-05≥186 (partial coverage)≥70 (partial coverage)
2025-06≥140 (partial coverage)≥72 (partial coverage)
2025-07≥223 (partial coverage)≥73 (partial coverage)
2025-08≥161 (partial coverage)≥74 (partial coverage)
2025-09≥195 (partial coverage)≥70 (partial coverage)
2025-10≥201 (partial coverage)≥70 (partial coverage)
2025-11≥141 (partial coverage)≥68 (partial coverage)
2025-12≥159 (partial coverage)≥94 (partial coverage)

Empty dashed outlines mark uncollected periods. Hatched bars and ≥ counts mark partial coverage.

Publication timing follows examination and publication cycles, not R&D intensity.

What makes it comparableThe same publication window and counting units. Companies with different windows are not put in one comparison.

What is not comparableGroup totals. Business and entity scopes differ; compare scale within a field or subclass.

Not a rankingSimilarity and shares describe structure, not patent value, quality or technical leadership.